A Phase I Safety Trial of CTX0E03 Drug Product Delivered Intracranially in the Treatment of Patients With Stable Ischemic Stroke
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
At a glance
- Drugs ReN 001 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms PISCES
- Sponsors ReNeuron
- 10 Jun 2017 Biomarkers information updated
- 04 Oct 2016 Results were published in The Lancet.
- 18 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2023, as reported by ClinicalTrials.gov.